Novartis AG is 199.0x more valuable than ArriVent BioPharma, Inc. by market capitalization ($282.64 B vs $1.42 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | AVBP | NVS |
|---|---|---|
| Market cap | $1.42 B | $282.64 B |
| US-listed rank | #2366 | #47 |
| Net income (latest FY) | -$166.31M | - |
| SEC filings | 144 | 947 |
Novartis AG is 199.0x more valuable than ArriVent BioPharma, Inc. by market capitalization ($282.64 B vs $1.42 B).
Full pages: ArriVent BioPharma, Inc. and Novartis AG, or browse the full rankings.